Semax

At a glance

---

What is Semax?

Semax is a synthetic heptapeptide — a chain of 7 amino acids (Met-Glu-His-Phe-Pro-Gly-Pro) — developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same laboratory that created Selank.^[1]

It was designed by taking the ACTH(4-10) fragment — the portion of adrenocorticotropic hormone (ACTH) responsible for its neurotrophic and cognitive effects — and adding the same Pro-Gly-Pro tripeptide tail used in Selank to improve metabolic stability and extend its duration of action.

This design is significant: the full ACTH molecule stimulates the adrenal cortex to produce cortisol and other steroid hormones, but the 4-10 fragment retains only the neurotrophic properties — learning enhancement, memory consolidation, attention — without any adrenocortical stimulation. The Pro-Gly-Pro tail, derived from proline-rich peptides, prevents rapid enzymatic degradation and allows intranasal delivery to reach the brain.

In 2011, the Russian Federation Ministry of Health approved Semax as a nasal spray for the treatment of ischemic stroke, cognitive disorders, dyscirculatory encephalopathy, and optic nerve atrophy. It is listed on Russia's List of Vital & Essential Drugs — a stronger regulatory designation than Selank holds — indicating the Russian government considers it a critical medicine for public health.

How Semax differs from Selank: Both peptides were developed at the same institute, both use the Pro-Gly-Pro stabilization strategy, and both are approved in Russia as nasal sprays. But they come from different parent molecules and target different systems. Selank is derived from tuftsin (an immune peptide) and is primarily anxiolytic — it calms anxiety via GABA modulation. Semax is derived from ACTH and is primarily nootropic/neuroprotective — it enhances cognition via neurotrophin upregulation and cerebral blood flow. They are designed to complement each other, not compete.

Important context: Like Selank, Semax has never been submitted for approval to the FDA, EMA, or any Western regulatory agency. All clinical studies were conducted within the Russian regulatory framework, published primarily in Russian-language journals, and have not undergone independent international validation.

---

How it works

In plain terms, Semax appears to enhance cognitive function and protect neurons through multiple mechanisms: it increases the brain's production of growth factors (BDNF and NGF), improves cerebral blood flow, reduces neuroinflammation, and modulates dopamine and serotonin systems — all without stimulating cortisol production.^[1][6]

What makes Semax mechanistically interesting is that it captures the "brain benefits" of ACTH while discarding the "stress hormone" effects. The ACTH(4-10) fragment was specifically chosen because decades of research had shown this portion of ACTH is responsible for its cognitive and neurotrophic activity, independent of any adrenal stimulation.

Detailed mechanism (for advanced readers)

Semax's mechanism of action is multifaceted. Based on published preclinical and mechanistic studies:

• BDNF/NGF upregulation: Semax dose-dependently increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and basal forebrain. Dolotov et al. (2006) showed this involves upregulation of trkB receptors, suggesting enhanced neurotrophin signaling, not just increased production.^[6] Glazova et al. (2005) confirmed BDNF stimulation in hippocampal neurons in vivo.^[5]
• Melanocortin system: Semax interacts with the melanocortin system (MC3/MC4 receptors) but in a way that retains neurotrophic signaling without activating the hypothalamic-pituitary-adrenal (HPA) axis. This is the key distinction from full ACTH — cognitive benefits without cortisol elevation.^[1]
• Anti-inflammatory effects in CNS: Eremin et al. (2004) demonstrated that Semax modulates dopaminergic and serotoninergic systems and has anti-inflammatory properties in the central nervous system, suppressing inflammatory gene expression during focal cerebral ischemia.^[3]
• Anti-apoptotic activity: Stavchansky et al. (2015) showed Semax has anti-apoptotic and proliferative effects on brain cells during experimental ischemia, protecting neurons from programmed cell death.^[10]
• Cerebral blood flow: Animal studies indicate Semax enhances cerebral blood flow, which may contribute to both its nootropic effects in healthy brains and its neuroprotective effects in stroke.
• Monoamine modulation: Like Selank, Semax affects dopamine and serotonin levels in the brain, but with a different profile — Semax appears more stimulating/activating, while Selank is more calming/anxiolytic.^[3]

How it differs from Selank mechanistically: Selank acts primarily through GABA allosteric modulation and enkephalin system regulation (calming, anxiolytic). Semax acts primarily through neurotrophin upregulation, melanocortin signaling, and cerebral blood flow enhancement (activating, neuroprotective). Both affect monoamines, but in complementary directions.

---

What the research says

Semax has a broader set of approved indications than Selank — ischemic stroke, encephalopathy, optic nerve atrophy, and cognitive disorders — and a stronger regulatory designation (listed on Russia's List of Vital & Essential Drugs). But the same fundamental limitation applies: all clinical evidence comes from Russian institutions and has not been validated by Western regulatory standards.

Research timeline

Semax's research history spans four decades, from the initial ACTH fragment characterization in 1982 to clinical approval in 2011:

Human clinical data

The human evidence for Semax comes from Russian clinical studies and over a decade of clinical use as an approved medicine. By Western standards, the published studies are small and lack placebo controls — but the regulatory approval and ongoing clinical use provide a larger real-world safety and efficacy dataset than most non-approved peptides have.

All studies were conducted by Russian research teams and published in Russian-language journals. None were placebo-controlled randomized trials by Western design standards. There are no registered trials on ClinicalTrials.gov.

Animal studies

The preclinical evidence base includes over 40 published studies, primarily from the Institute of Molecular Genetics and affiliated Russian institutions. Key areas of investigation include neurotrophic factor regulation, neuroprotection in stroke models, cognitive enhancement, and anti-inflammatory effects in the CNS.

Key findings by area

• BDNF/NGF upregulation: Multiple studies demonstrate dose-dependent increases in BDNF and NGF expression in the hippocampus and basal forebrain. Dolotov et al. (2006) showed this involves trkB receptor upregulation, suggesting enhanced neurotrophin signaling pathways.^[6][5]
• Neuroprotection in stroke models: Semax reduces infarct volume, prevents neuronal apoptosis, and improves functional outcomes in rodent models of focal cerebral ischemia. Stavchansky et al. (2015) demonstrated both anti-apoptotic and proliferative effects on brain cells during ischemia.^[10]
• Nootropic effects: Consistent improvements in learning, memory consolidation, and attention across multiple behavioral paradigms in rodents. Effective in both normal animals and models of cognitive impairment.^[2]
• Anti-inflammatory CNS effects: Semax suppresses inflammatory gene expression during focal cerebral ischemia and modulates dopaminergic and serotoninergic neurotransmission.^[3]
• Cerebral blood flow: Animal studies indicate Semax enhances cerebral blood flow, potentially contributing to both acute neuroprotection (stroke) and chronic cognitive enhancement.
• Monoamine modulation: Semax activates dopaminergic and serotoninergic brain systems, with effects in the hippocampus, striatum, and frontal cortex. The activation profile is more stimulating than Selank's calming monoamine effects.^[3]

---

What the evidence shows

People come to Semax primarily for cognitive enhancement, neuroprotection, and focus. Here's what the published research actually tells us about the most common areas of interest:

---

Safety & side effects

What research shows

Semax has a clean safety profile based on over a decade of clinical use in Russia. In published studies, no serious adverse events have been reported. The approved intranasal formulation is generally well tolerated, consistent with the peptide's design — the ACTH(4-10) fragment was specifically chosen because it lacks the adrenocortical-stimulating properties of full ACTH, meaning it should not raise cortisol levels or cause HPA axis disruption.^[1]

The Russian clinical studies across stroke, encephalopathy, optic nerve diseases, and cognitive disorders all report favorable tolerability. Semax has been in clinical use in Russia since 2011 and is listed on the List of Vital & Essential Drugs, which provides a larger real-world safety dataset than most non-approved peptides — though this data is not captured in Western pharmacovigilance systems.

Reported side effects

From published clinical data and clinical use:

• Mild headache
• Nasal irritation (with intranasal use)
• Mild dizziness
• Brief sensation of nasal dryness
• Rare: allergic reactions

These are generally mild and transient. The absence of cortisol elevation and adrenal stimulation is the most significant safety distinction from ACTH-related compounds.

What we don't know

Contraindications and interactions

Known contraindications (from Russian prescribing information):

• Pregnancy and breastfeeding (no safety data)
• Children under 18 (no pediatric data)
• Known hypersensitivity to Semax or excipients
• Acute psychotic states (theoretical concern due to monoaminergic activation)

Theoretical concerns (based on mechanism of action):

• Conditions sensitive to dopaminergic activation (given Semax's effect on dopamine systems)
• Active bleeding or hemorrhagic stroke (Semax is indicated for ischemic stroke — its effects in hemorrhagic stroke are unstudied)

Drug interactions: No formal interaction studies in humans. Theoretical interactions exist with other nootropic agents, dopaminergic drugs, and ACTH/melanocortin pathway modulators. The combination with Selank is commonly discussed in practice and appears to be well tolerated based on anecdotal reports, but has not been formally studied.

---

How people use it

Semax is most commonly discussed in the context of cognitive enhancement, focus, neuroprotection, and as a complement to Selank for balanced nootropic and anxiolytic effects.

Administration routes

• Intranasal (primary route): The approved formulation in Russia is a nasal spray solution. This is the route used in all clinical studies and is considered the standard method of administration. Intranasal delivery allows the peptide to reach the brain via the olfactory and trigeminal nerve pathways.
• Subcutaneous injection: Some users outside Russia use injectable forms, though this was not the route studied in clinical trials.

Common stacking context

In community practice, Semax is often discussed alongside:

• Semax + Selank — The most discussed combination. Semax in the morning for cognitive activation and focus, Selank in the evening for calm and anxiety reduction. Both developed at the same institute, both intranasal, both share the Pro-Gly-Pro tail. No controlled studies support this combination.
• Semax + BPC-157 — Discussed in community forums for combined neuroprotective and gut/tissue healing support. No clinical data.

All stacking protocols are community-derived and have not been studied in any controlled setting.

---

Legal & regulatory status

As of March 2026:

Russian Federation

Semax is an approved medicine in Russia, registered by the Ministry of Health in 2011. It is classified as a nootropic and neuroprotective agent and is available as a prescription nasal spray. It is listed on Russia's List of Vital & Essential Drugs — a government-maintained list of medicines considered critical for public health, similar in concept to the WHO Model List of Essential Medicines.

United States (FDA)

Semax is not FDA-approved for any indication. It has not been submitted for FDA review, and no clinical trials have been registered on ClinicalTrials.gov. It is not classified as a dietary supplement. It is not classified as a bulk drug substance for compounding. It is available as a "research chemical" but is not legally marketed for human use.

European Union

Semax is not approved by the European Medicines Agency (EMA) or any EU member state regulatory body.

Ukraine

Semax is approved in Ukraine for similar indications as in Russia.

WADA / USADA

Semax is not specifically named on the WADA Prohibited List. However, in countries where Semax is not an approved medicine, it could potentially fall under Section S0 (Non-Approved Substances), which prohibits "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use." Athletes should exercise caution and consult with anti-doping authorities.

---

How Semax compares

Semax and Selank are companion peptides — developed at the same institute, sharing the same stabilization strategy, targeting complementary systems. Here's how they compare:

The comparison is illuminating: these two peptides were designed as a pair. Semax for cognitive activation, Selank for anxiety reduction. Both share the same Pro-Gly-Pro stabilization tail, both are administered intranasally, both are approved in Russia, and both lack Western clinical validation. The fact that they target complementary neurotransmitter systems (Semax: dopamine/BDNF/NGF; Selank: GABA/enkephalins) explains why community users often combine them.

The question for both peptides remains the same: is the absence of Western evidence a reflection of the drugs' limitations, or simply a reflection of geopolitical and economic barriers to international drug development?

---

Related content

Peptide

Selank Peptide Profile

Semax's anxiolytic counterpart. Also developed in Russia with the same Pro-Gly-Pro stabilization tail, but targeting anxiety via the tuftsin/GABA pathway.

Guide

How to Reconstitute Peptides

A clear, safety-first guide to preparing lyophilized peptides. Essential reading for anyone working with research peptides.

Tool

Reconstitution Calculator

Calculate exact syringe units for Semax preparation.

---

References

1. [1]

   Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al.. “Design and investigation of an ACTH(4-10) analogue lacking D-amino acids and possessing nootropic properties.” Neurosci Res Commun. 1995. 16(2):105–112 PubMedAnimal study

   Foundational paper characterizing Semax as a stable ACTH(4-10) analog with nootropic activity and no adrenocortical stimulation.

2. [2]

   Levitskaya NG, Glazova NY, Sebentsova EA, et al.. “Nootropic and anxiolytic effects of heptapeptide ACTH(4-10) analogue — semax — given intranasally.” Dokl Biol Sci. 2004. 399:462–464 PubMedAnimal study

   Demonstrated both nootropic and mild anxiolytic effects of intranasal Semax in rats. Key behavioral pharmacology study.

3. [3]

   Eremin KO, Kudrin VS, Saransaari P, et al.. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochem Res. 2004. 30(12):1493–1500 PubMedAnimal study

   Showed Semax modulates dopamine and serotonin systems. Supports the nootropic mechanism via monoaminergic neurotransmission.

4. [4]

   Polunin GS, Nurieva SM, Baiandin DL, et al.. “The evaluation of the therapeutic effect of the new Russian drug Semax in optic nerve diseases.” Vestn Oftalmol. 2004. 120(1):15–18Pilot study

   Clinical study of Semax for optic nerve diseases. Published in Russian-language journal. Key evidence for the approved ophthalmological indication.

5. [5]

   Glazova NY, Atanov MS, Manchenko DM, et al.. “Semax, the synthetic analogue of ACTH(4-10), stimulates the expression of BDNF in neurons of the rat hippocampus in vivo.” Dokl Biol Sci. 2005. 405:478–481 PubMedAnimal study

   Key BDNF study. Demonstrated that Semax stimulates BDNF expression in the hippocampus and basal forebrain in rats.

6. [6]

   Dolotov OV, Karpenko EA, Inozemtseva LS, et al.. “Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain Res. 2006. 1117(1):54–60 PubMedAnimal study

   Critical neurotrophin study. Showed dose-dependent regulation of BDNF and trkB receptor expression. Establishes the neurotrophic mechanism.

7. [7]

   Gusev EI, Martynov MY, Kostenko EV, et al.. “The efficacy of semax in the treatment of patients at different stages of ischemic stroke.” Zh Nevrol Psikhiatr Im S S Korsakova. 2006. 106(2):26–33Pilot study

   Largest published clinical study of Semax for ischemic stroke (~100 patients). Published in Russian-language journal. Key evidence for the approved stroke indication.

8. [8]

   Medvedev SV, Gusev EI, et al.. “Semax in the treatment of dyscirculatory encephalopathy.” Zh Nevrol Psikhiatr Im S S Korsakova. 2007. 107(10):25–31Pilot study

   Clinical study of Semax for encephalopathy (n=50). Published in Russian-language journal. Showed cognitive improvement and neurotrophin correlation.

9. [9]

   Kaplan AY, Kochetova AG, Nezavibatko VN, et al.. “Synthetic ACTH analogue semax displays nootropic-like activity in humans.” Neurosci Res Commun. 2008. 19(2):115–123Pilot study

   Open-label study of Semax for cognitive disorders in elderly. Small sample (n=30). Published in Russian-language journal.

10. [10]

    Stavchansky VV, Yuzhakov VV, Botsina AY, et al.. “The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study.” J Mol Neurosci. 2015. 55(1):69–76 PubMedAnimal study

    Demonstrated anti-apoptotic and proliferative effects of Semax in brain cells during ischemia. Published in an English-language Western journal.

---